( he Saint Louis University School ofMed...)Accentia Biopharmaceuticals Scientific Presentations Demonstrate,Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at,the Annual Meeting of the American Academy of Allergy, Asthma, and,Immunology,Health

he Saint Louis University School of Medicine, said, "The potential identification of an etiology for chronic sinusitis, and the subsequent development of an effective pharmacotherapy, would represent an important advance in the treatment of patients suffering from surgery refractory chronic sinusitis. This is one of the most common chronic illnesses, affecting millions, and the potential of intranasal antifungals to significantly reduce morbidity is tremendous."

Accentia has received Fast Track status from the Food and Drug Administration for SinuNase, and has initiated a Phase 3 clinical trial at sites across the U.S., in patients with severe chronic sinusitis who have had one or more prior sinus surgeries. Patients who believe they may be eligible to participate in a clinical trial with SinuNase are encouraged to visit www.accentia.net/patients/trials_sinunase.php, or call 212-686-4100.

About Accentia Biopharmaceuticals, Inc.

Accentia Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development of late-stage "disruptive" clinical products, especially for already-approved drugs in new formulations and/or new indications that are patent-protected and which represent new therapeutics with greater clinical and economic value. Accentia has a pipeline of products in late-stage clinical development. The company's lead respiratory product candidate is SinuNase(TM), which is under clinical development to treat chronic sinusitis (rhinosinusitis). SinuNase is a novel application and formulation of a known anti-fungal exclusively licensed from the Mayo Foundation for Medical Education and Research. The product has been Fast Tracked by the FDA and the Company has commenced a Phase 3 clinical trial. The Company's other lead product is BiovaxID(TM), a patient-specific anti-cancer vaccine for the treatment of follicular non-Hodgkin's lymphoma. BiovaxID, which is being developed by Accentia's subsidiary, Biovest International, Inc., (OTCB
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
5. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
6. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
7. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
10. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
11. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions